Georgina Gener-Ricos
Assitant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Year:
2026
Therapy-related myeloid neoplasms (t-MNs) arise after exposure to cytotoxic therapies and are associated with high-risk genetic features and poor outcomes. We analyzed a cohort of patients with therapy-related chronic myelomonocytic leukemia (tCMML; n = 71) and compared its features to that of de novo CMML (dnCMML; n = 461). Median time from cytotoxic therapy to tCMML diagnosis was 6.5 years. Compared with dnCMML, chromosome 7 abnormalities (4% vs. 13%; P = .005), but not complex karyotype (3% vs. 7%; P = .15), were more frequent in tCMML. tCMML was characterized by higher TP53 mutation frequency (4% vs. 12%; P = .04) and lower NRAS (6% vs 22%, P =0.007) and CBL (4% vs 12%, P =0.04) mutation frequency. Prior therapy with antimetabolites (OR, 1.22 [95% CI, 1.05-1.42]; P = .01) and mitotic inhibitors (OR, 1.24 [95% CI, 1.06-1.44]; P = .009) was associated with NF1 and SETBP1 mutations while prior mitotic inhibitor therapy was associated with lower TET2 mutation frequency (OR, 0.71 [95% CI, 0.55-0.92]; P = .01). Although no differences in median overall survival (OS) were observed among tCMML and dnCMML (34.7 months vs 35.9 months, P = .26), multivariate analysis for OS revealed that prior chemotherapy was associated with increased risk of death (HR 1.76 [95% CI, 1.07-2.89]; P = .026). Compared to a cohort of therapy-related myelodysplastic syndrome, tCMML had lower TP53 mutation frequency (12% vs 44.4%, P <.001) and less unfavorable outcomes. In summary, tCMML does not exhibit the high-risk features and poor outcomes of t-MNs. -
Year:
2024
Year:
2024
Introduction NPM1 ‐mutated ( NPM1 mut ) myeloid neoplasms (MNs) with <20% bone marrow (BM) blasts ( NPM1 mut MNs<20) are uncommon, and their classification remains inconsistent. Methods The clinicopathologic features of 54 patients with NPM1 mut MNs <20 were evaluated and compared with wild‐type NPM1 MNs <20 and NPM1 mut MNs≥20, respectively. Results NPM1 mut MNs had similar features regardless of blast percentage, except for higher IDH2 (29% vs 7%, p = .023) and FLT3 (70% vs 11%, p < .001) frequency in patients with ≥20% BM blasts. Thirty‐three (61%) patients with NPM1 mut MNs <20 received low‐intensity chemotherapy (LIC) and 12 (22%) received intensive chemotherapy (IC). Higher complete remission rates (75% vs 27%, p = .006) and median overall survival (mOS) (not reached vs 30.4 months, p = .06) were observed with IC compared to LIC. Young patients (age <60 years) did not reach mOS either when treated with LIC or IC. Stem cell transplant was associated with increased survival only in patients treated with LIC (HR, 0.24; p = .025). No differences in mOS were observed by BM blast strata (32.2 months, not reached and 46.9 months for <10%, 10%–19%, and ≥20% blasts, p = .700) regardless of treatment modality (LIC: p = .900; IC: p = .360). Twenty‐three patients (43%) with NPM1 mut MNs <20 had marrow blast progression to ≥20%. Conclusions Overall, NPM1 mut MNs define a unique entity independent of BM blast percentage.
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (7)
Samuel Urrutia
Assistant Professor of Medicine
Washington University in St. Louis
Hagop Kantarjian
-
Alex Bataller Torralba
The University of Texas MD Anderson Cancer Center
Guillermo Montalban-Bravo
Assistant Professor
The University of Texas MD Anderson Cancer Center
Rashmi Kanagal Shamanna
The University of Texas MD Anderson Cancer Center
Elizabeth Burton
The University of Texas MD Anderson Cancer Center
colm keane
Lab head
University of Queensland
Make your next move.
Prepare your application
Review drafts before you send them.